Business Description
AdAlta is an Australian biotechnology company that develops new treatments for serious diseases using its proprietary i-body platform. Its main drug candidate, AD-214, is currently in Phase II clinical trials targeting fibrosis conditions affecting the lungs, eyes, liver, skin, and kidneys, as well as age-related macular degeneration. Working alongside La Trobe University, the company has also developed WD-34, a potential treatment for malaria and related parasitic infections. Founded in 2006, AdAlta is headquartered in Camberwell, Australia.
